27 results
424B5
ENLV
Enlivex Therapeutics Ltd
29 May 24
Prospectus supplement for primary offering
4:15pm
and the investor. The Engagement Agreement does not give rise to any commitment by the placement agent to purchase any of our securities, and the placement agent
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
of our securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
their efforts and commitment, and we wish them continued success in their individual paths forward. Our reprioritization is expected to decrease
6-K
EX-99.1
k3ujp1kxl rjyx6
29 Aug 22
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells
8:01am
6-K
EX-99.1
lh3js5pi1vvmc5
30 Sep 21
Annual and Extraordinary General Meeting of Shareholders
8:01am
FWP
c1rp uknq0s8p
10 Feb 21
Free writing prospectus
6:08am
FWP
y2yle
9 Feb 21
Free writing prospectus
5:21pm
6-K
EX-10.1
rim dktvtejj3
22 Oct 20
Report of Foreign Private Issuer
8:47am
6-K
EX-99.1
h6kys1ucu h2sb87lwta
19 May 20
Annual and Extraordinary General Meeting of Shareholders
8:04am
424B5
mafd7a8l5mf 1ab07
3 Mar 20
Prospectus supplement for primary offering
5:13pm
424B5
dz93q08
26 Feb 20
Prospectus supplement for primary offering
8:23am